Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher BioSpacePartner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner's National Priority Voucher to accelerate drug review.OncologyRead full story pharminent May 11, 2026 (Last updated: May 11, 2026) BioSpace Partner Therapeutics announced last week that the FDA had granted Bizengri a Commissioner’s National Priority Voucher to accelerate drug review. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Deal finally unlocks NHS access to ITF’s Duchenne drugNext: Novo Nordisk microRNA drug fluffs its lines in heart failure Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
